EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma

Yuan-Hong Huang, Chao-Ling Wan, Hai-Ping Dai iD, Sheng-Li Xue

Annals of Hematology · 2023

DOI: 10.1007/s00277-023-05286-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2023. Verfasst von Yuan-Hong Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Immunotherapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaLymphomaMolecular Targeted TherapyHumansT-Lymphocytes

Stichwörter der Autor:innen

ImmunotherapyT cell acute lymphoblastic leukemia/lymphomaTargeted therapy

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. daihaiping8@126.com.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China. daihaiping8@126.com.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. slxue@suda.edu.cn.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China. slxue@suda.edu.cn.

ORCID-Profile: Hai-Ping Dai

Zitieren

APA

Huang, Y. H., Wan, C. L., Dai, H. P., & Xue, S. L. (2023). Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-023-05286-3

Vancouver

Huang YH, Wan CL, Dai HP, Xue SL. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of Hematology. 2023. doi:10.1007/s00277-023-05286-3

BibTeX
@article{Huang2023,
  author = {Huang, Yuan-Hong and Wan, Chao-Ling and Dai, Hai-Ping and Xue, Sheng-Li},
  title = {Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma},
  journal = {Annals of Hematology},
  year = {2023},
  doi = {10.1007/s00277-023-05286-3}
}
Kostenlos starten →